← ATYR
ATYR— aTYR PHARMA INC
MaterialsBiological Products, (No Diagnostic Substances)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Total revenues | $190K-19.1% | $235K-33.4% | $353K-96.6% | $10.4M-0.7% | $10.5M | — | — |
| Research and development | $60.2M+10.8% | $54.4M+28.6% | $42.3M-1.2% | $42.8M+84.0% | $23.3M+34.5% | $17.3M+23.1% | $14.0M |
| General and administrative | $17.6M+27.7% | $13.8M+6.1% | $13.0M-7.2% | $14.0M+30.1% | $10.8M+18.5% | $9.1M-3.0% | $9.4M |
| Total operating expenses | $77.8M+14.2% | $68.1M+23.3% | $55.3M-2.7% | $56.8M+67.0% | $34.0M+29.0% | $26.4M+12.7% | $23.4M |
| Loss from operations | -$77.6M-14.3% | -$67.9M-23.7% | -$54.9M-18.3% | -$46.4M-36.4% | -$34.0M-113.8% | -$15.9M+30.8% | -$23.0M |
| Total other income (expense), net | $3.5M-10.0% | $3.9M-13.9% | $4.5M+326.2% | $1.1M+345.8% | $238K+174.6% | -$319K+59.4% | -$785K |
| Consolidated net loss | -$74.1M-15.8% | -$64.0M-27.0% | -$50.4M-11.1% | -$45.3M-34.2% | -$33.8M-108.1% | -$16.2M+31.7% | -$23.8M |
| Net loss (gain) attributable to noncontrolling interest in Pangu BioPharma Limited | $5K+600.0% | -$1K-112.5% | $8K+60.0% | $5K-44.4% | $9K+50.0% | $6K-96.3% | $160K |
| Net loss attributable to aTyr Pharma, Inc. | -$74.1M-15.8% | -$64.0M-27.1% | -$50.4M-11.1% | -$45.3M-34.3% | -$33.8M-108.1% | -$16.2M+31.3% | -$23.6M |
| Net loss per share - basic | -$800+7.0% | -$860+8.5% | -$940+41.3% | -$2K+9.6% | -$2K+0.0% | -$2K | — |
| Net loss per share - diluted | -$800+7.0% | -$860+8.5% | -$940+41.3% | -$2K+9.6% | -$2K+0.0% | -$2K | — |
| Shares used in computing net loss per share, basic | $92.99B+25.2% | $74.26B+38.5% | $53.61B+88.6% | $28.42B+48.9% | $19.08B+108.3% | $9.16B | — |
| Shares used in computing net loss per share, diluted | $92.99B+25.2% | $74.26B+38.5% | $53.61B+88.6% | $28.42B+48.9% | $19.08B+108.3% | $9.16B | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.